» Articles » PMID: 18607850

Prognostic Significance of Numeric Aberrations of Genes for Thymidylate Synthase, Thymidine Phosphorylase and Dihydrofolate Reductase in Colorectal Cancer

Overview
Journal Acta Oncol
Specialty Oncology
Date 2008 Jul 9
PMID 18607850
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Most human cancer cells have structural aberrations of chromosomal regions leading to loss or gain of gene specific alleles. This study aimed to assess the range of gene copies per nucleus of thymidylate synthase (TYMS), thymidine phosphorylase (TP) and dihydrofolate reductase (DHFR) in colorectal cancer, and to evaluate its prognostic significance following adjuvant chemotherapy, since these enzymes are closely related to efficacy of 5-fluorouracil (5FU).

Patients And Methods: Consecutive patients (n = 314), who were completely resected for colorectal cancer stages II-IV and adjuvantly treated with 5-FU were retrospectively evaluated. Paraffin embedded tumor specimens were assessed for gene copies per nucleus of TYMS, TP and DHFR by fluorescence in situ hybridisation (FISH) using specific peptide nucleic acid probes. Outcome according to gene copies per nucleus above and below the median were compared. Also TYMS expression, assessed by immunohistochemistry, was associated with TYMS copies per nucleus.

Results: The number of gene copies per nucleus were 1.7 (0.7-2.8), 1.8 (0.9-3.1) and 1.8 (1.1-2.7) median (range) for TYMS, TP and DHFR, respectively. TYMS expression was directly associated with TYMS genes per nucleus (p = 0.05). Cox multivariate analysis, adjusted for the prognostic impact of disease stage, vascular tumor invasion, and bowel obstruction at resection, revealed that high TYMS gene copy number was associated with significantly higher risk of recurrence (HR = 1.6; 95%CI 1.1-2.2; p = 0.02) and death (HR = 1.6; 95%CI 1.1-2.3; p = 0.01). No significant differences in outcome appeared according to TP and DHFR gene ratios.

Conclusion: Aberration of TYMS gene is of significance to expression of TYMS, which may influence the biology and 5-FU sensitivity of colorectal cancer. This may be utilized in the allocation of patients for treatment approaches and for decision on follow-up programs.

Citing Articles

Prognostic value of folate-associated gene expression in stage II colon cancer.

Kaidi D, Odin E, Wettergren Y, Bexe Lindskog E J Cancer Res Clin Oncol. 2025; 151(2):92.

PMID: 39998667 PMC: 11861115. DOI: 10.1007/s00432-025-06141-w.


Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer....

Guadagni S, Masedu F, Fiorentini G, Sarti D, Fiorentini C, Guadagni V BMC Cancer. 2022; 22(1):660.

PMID: 35710393 PMC: 9202660. DOI: 10.1186/s12885-022-09770-3.


Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer.

Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C Clin Transl Med. 2021; 11(4):e401.

PMID: 33931971 PMC: 8087915. DOI: 10.1002/ctm2.401.


A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer.

Guadagni S, Clementi M, Masedu F, Fiorentini G, Sarti D, Deraco M Int J Mol Sci. 2020; 21(13).

PMID: 32646060 PMC: 7370156. DOI: 10.3390/ijms21134813.


Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.

Guadagni S, Fiorentini G, De Simone M, Masedu F, Zoras O, Mackay A J Cancer Res Clin Oncol. 2019; 146(1):205-219.

PMID: 31620896 PMC: 6942036. DOI: 10.1007/s00432-019-03046-3.